BIIB122, Placebo to BIIB122
DNLI-C-0009
Phase 2 small_molecule active
Quick answer
BIIB122, Placebo to BIIB122 for Parkinson’s disease is a Phase 2 program (small_molecule) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Parkinson’s disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active